Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 12.56 Billion INR | 32.89% |
| 2022 | 8.81 Billion INR | -13.83% |
| 2021 | 10.44 Billion INR | 0.15% |
| 2020 | 10.24 Billion INR | 29.04% |
| 2019 | 7.71 Billion INR | 35.98% |
| 2018 | 5.87 Billion INR | -14.29% |
| 2017 | 6.82 Billion INR | -5.75% |
| 2016 | 7.1 Billion INR | 19.98% |
| 2015 | 6.05 Billion INR | 15.82% |
| 2014 | 5.13 Billion INR | 36.44% |
| 2013 | 3.82 Billion INR | 69.51% |
| 2012 | 2.3 Billion INR | 52.64% |
| 2011 | 1.46 Billion INR | 48.24% |
| 2010 | 991.36 Million INR | 24.56% |
| 2009 | 796.54 Million INR | 17.8% |
| 2008 | 667.11 Million INR | 27.73% |
| 2007 | 528.97 Million INR | 30.63% |
| 2006 | 404.93 Million INR | 14.89% |
| 2005 | 350 Million INR | 22.46% |
| 2004 | 287.68 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 3.3 Billion INR | 0.09% |
| 2024 Q1 | 3.3 Billion INR | 5.27% |
| 2023 Q4 | 2.78 Billion INR | -15.06% |
| 2023 Q1 | 3.03 Billion INR | 62.77% |
| 2023 Q2 | 3.11 Billion INR | 2.94% |
| 2023 FY | - INR | 32.89% |
| 2023 Q3 | 3.27 Billion INR | 5.02% |
| 2022 Q4 | 1.86 Billion INR | -8.94% |
| 2022 FY | - INR | -13.83% |
| 2022 Q2 | 2.36 Billion INR | -7.01% |
| 2022 Q3 | 2.04 Billion INR | -13.61% |
| 2022 Q1 | 2.54 Billion INR | 7.77% |
| 2021 FY | - INR | 0.15% |
| 2021 Q4 | 2.36 Billion INR | -10.41% |
| 2021 Q1 | 2.52 Billion INR | -3.47% |
| 2021 Q3 | 2.63 Billion INR | -9.83% |
| 2021 Q2 | 2.92 Billion INR | 15.63% |
| 2020 Q3 | 2.47 Billion INR | -11.44% |
| 2020 Q4 | 2.61 Billion INR | 5.98% |
| 2020 FY | - INR | 29.04% |
| 2020 Q1 | 2.36 Billion INR | 5.28% |
| 2020 Q2 | 2.79 Billion INR | 18.09% |
| 2019 Q3 | 2 Billion INR | 5.11% |
| 2019 Q2 | 1.9 Billion INR | 8.43% |
| 2019 Q1 | 1.76 Billion INR | 36.76% |
| 2019 FY | - INR | 35.98% |
| 2019 Q4 | 2.24 Billion INR | 11.9% |
| 2018 FY | - INR | -14.29% |
| 2018 Q4 | 1.28 Billion INR | 15.21% |
| 2018 Q3 | 1.11 Billion INR | -38.43% |
| 2018 Q2 | 1.81 Billion INR | 9.56% |
| 2018 Q1 | 1.65 Billion INR | 14.4% |
| 2017 Q2 | 1.92 Billion INR | 45.9% |
| 2017 Q1 | 1.32 Billion INR | -19.27% |
| 2017 FY | - INR | -5.75% |
| 2017 Q4 | 1.44 Billion INR | -31.92% |
| 2017 Q3 | 2.12 Billion INR | 10.23% |
| 2016 Q3 | 1.97 Billion INR | 9.61% |
| 2016 Q2 | 1.79 Billion INR | 4.56% |
| 2016 Q1 | 1.72 Billion INR | 17.19% |
| 2016 FY | - INR | 19.98% |
| 2016 Q4 | 1.63 Billion INR | -16.93% |
| 2015 Q4 | 1.46 Billion INR | -11.07% |
| 2015 FY | - INR | 15.82% |
| 2015 Q2 | 1.59 Billion INR | 23.31% |
| 2015 Q3 | 1.65 Billion INR | 3.67% |
| 2015 Q1 | 1.29 Billion INR | -4.22% |
| 2014 Q1 | 1.01 Billion INR | 0.0% |
| 2014 Q4 | 1.34 Billion INR | -9.69% |
| 2014 FY | - INR | 36.44% |
| 2014 Q3 | 1.49 Billion INR | 12.06% |
| 2014 Q2 | 1.33 Billion INR | 31.35% |
| 2013 FY | - INR | 69.51% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | - INR | 52.64% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | - INR | 48.24% |
| 2010 FY | - INR | 24.56% |
| 2009 FY | - INR | 17.8% |
| 2008 FY | - INR | 27.73% |
| 2007 FY | - INR | 30.63% |
| 2006 FY | - INR | 14.89% |
| 2005 FY | - INR | 22.46% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -30.662% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 79.664% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -83.092% |
| Granules India Limited | 8.6 Billion INR | -46.044% |
| Indoco Remedies Limited | 2.64 Billion INR | -374.694% |
| Achyut Healthcare Limited | 524 Thousand INR | -2397877.099% |
| Alkem Laboratories Limited | 24.19 Billion INR | 48.066% |
| Alpa Laboratories Limited | 86.12 Million INR | -14489.385% |
| Brooks Laboratories Limited | 41.72 Million INR | -30012.634% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -433.155% |
| Bajaj HealthCare Limited | 444.51 Million INR | -2726.76% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -749.57% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 85.766% |
| Eris Lifesciences Limited | 6.98 Billion INR | -79.854% |
| FDC Limited | 4.4 Billion INR | -185.468% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -10.77% |
| Gufic Biosciences Limited | 1.48 Billion INR | -748.735% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -83.125% |
| Ipca Laboratories Limited | 13.29 Billion INR | 5.52% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -3784.684% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 15288.995% |
| Lasa Supergenerics Limited | -65.08 Million INR | 19407.621% |
| Laurus Labs Limited | 8 Billion INR | -56.95% |
| Lupin Limited | 36.96 Billion INR | 66.011% |
| Mankind Pharma Limited | 28.09 Billion INR | 55.275% |
| Medicamen Biotech Limited | 245.66 Million INR | -5014.956% |
| Medico Remedies Limited | 150.37 Million INR | -8255.877% |
| Megasoft Limited | 284.73 Million INR | -4313.078% |
| NATCO Pharma Limited | 18.79 Billion INR | 33.145% |
| Piramal Pharma Limited | 13.05 Billion INR | 3.753% |
| RPG Life Sciences Limited | 1.28 Billion INR | -880.523% |
| Sigachi Industries Limited | 883.39 Million INR | -1322.394% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 90.919% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -168.653% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -2820.312% |
| Unichem Laboratories Limited | 742.35 Million INR | -1592.638% |
| Wanbury Limited | 985.49 Million INR | -1175.041% |
| Windlas Biotech Limited | 781.72 Million INR | -1507.404% |
| ZIM Laboratories Limited | 462.09 Million INR | -2619.213% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 77.65% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 436.76% |
| Divi's Laboratories Limited | 25.43 Billion INR | 50.588% |
| Hester Biosciences Limited | 539.47 Million INR | -2229.212% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -316.846% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1740.982% |
| Bal Pharma Limited | 345.59 Million INR | -3535.906% |
| Strides Pharma Science Limited | 3.76 Billion INR | -233.771% |
| Venus Remedies Limited | 711.8 Million INR | -1665.297% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -221.413% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -703.522% |
| Shilpa Medicare Limited | 2.58 Billion INR | -385.529% |
| Aarti Drugs Limited | 3.24 Billion INR | -286.791% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -382.061% |
| Suven Life Sciences Limited | -992.78 Million INR | 1365.678% |
| Ind-Swift Limited | 1.06 Billion INR | -1079.777% |
| Valiant Laboratories Limited | 12.73 Million INR | -98537.256% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -34.608% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 545.282% |
| Themis Medicare Limited | 562.6 Million INR | -2133.424% |
| Hikal Limited | 2.69 Billion INR | -366.728% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 64.109% |
| Sequent Scientific Limited | 549.8 Million INR | -2185.449% |
| Novartis India Limited | 1.26 Billion INR | -889.947% |
| Wockhardt Limited | 1.08 Billion INR | -1063.463% |
| Jubilant Pharmova Limited | 8 Billion INR | -56.95% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -96098.132% |
| Neuland Laboratories Limited | 4.74 Billion INR | -164.636% |
| Morepen Laboratories Limited | 1.72 Billion INR | -628.026% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -4271.714% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -7082.445% |